Evaluation of anti‑diabetic activity of methanolic extract from the bark of Atalantia monophylla (Linn.) in alloxan‑induced diabetic mice

Abstract

The objective of the present study was to evaluate the anti-diabetic activity of methanolic extract from the bark of Atalantia monophylla (Linn.) in alloxan-induced diabetic mice. Materials and Methods: Diabetes was induced in mice by injection of alloxan (200 mg/kg, i.p.). Diabetic mice were divided into different groups and methanolic bark extract of Atalantia monophylla (AMMt) was administered at dose ranges of 50–200 mg/kg, p.o for 14 days. Control group received normal saline (0.9%) for 14 days. Glibenclamide (4 mg/kg, p.o) was used as standard drug. Blood samples were collected from all the groups and analysed for serum glucose and lipid levels such as total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL). AMMt was also tested for oral glucose tolerance test (OGTT) in normal fasted rats. Results: AMMt (100 and 200 mg/kg, p.o) showed a significant (P<0.05) reduction of serum glucose level in alloxan-induced diabetic mice as compared with diabetic control. AMMt (100 and 200 mg/kg) also showed a significant reduction in serum TC, TG, LDL and VLDL levels in alloxan-induced diabetic mice. In addition, AMMt (100 and 200 mg/kg, p.o) significantly increased serum HDL level as compared with diabetic mice. AMMt (100 and 200 mg/kg, p.o) significantly (P<0.05) increased the glucose tolerance in OGTT. Conclusion: The results obtained from the present study revealed the potential anti-diabetic activity of methanolic extract from the bark of A. monophylla.